The Prognostic Value of SOX2 Expression in Non-Small Cell Lung Cancer: A Meta-Analysis

OBJECTIVE: To investigate the association of SOX2 expression in tumor with clinicopathological features and survival of non-small-cell lung carcinoma (NSCLC) patients. METHODS: Publications assessing the clinicopathological characteristics and prognostic significance of SOX2 in NSCLC were identified...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yansu, Huang, Yefei, Huang, Yulin, Chen, Junjie, Wang, Shouyu, Zhou, Jianwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747201/
https://www.ncbi.nlm.nih.gov/pubmed/23990933
http://dx.doi.org/10.1371/journal.pone.0071140
Descripción
Sumario:OBJECTIVE: To investigate the association of SOX2 expression in tumor with clinicopathological features and survival of non-small-cell lung carcinoma (NSCLC) patients. METHODS: Publications assessing the clinicopathological characteristics and prognostic significance of SOX2 in NSCLC were identified up to May 2013. A meta-analysis of eligible studies was performed using standard statistical methods to clarify the association between SOX2 expression and these clinical parameters. RESULTS: A total of eight studies met the inclusion criteria. Analysis of these data showed that SOX2 expression was positively associated with squamous histology, (pooled OR = 5.26, 95% CI: 1.08–25.6, P = 0.040). Simultaneously, we also found that SOX2 expression was positively associated with overall survival (pooled HR = 0.65, 95% CI: 0.47–0.89, P = 0.007, random-effect). CONCLUSIONS: SOX2 expression in tumor is a candidate positive prognostic biomarker for NSCLC patients.

Ejemplares similares